“…In addition, intravitreal triamcinolone acetonide (IVTA) has been used to reduce macular edema and subretinal exudation in Coats' disease [4,5]. Recently, it has been shown that intravitreal antivascular endothelial growth factor (VEGF) agents namely bevacizumab (Avastin Ò ; Genentech, San Francisco, CA, USA), a humanized monoclonal antibody to all isoforms of VEGF, effectively improved resorption of subretinal fluid and macular exudates when given to children with Coats' disease and may be employed alone [6,7] or with IVTA [8,9] or as adjunctive treatment to laser photocoagulation [8][9][10][11][12][13][14]. Only a single case report describes the use of intravitreal bevacizumab (IVBe) in adult-onset Coats' disease [15].…”